Exicure (XCUR) Projected to Post Earnings on Friday

Exicure (NASDAQ:XCUR) is projected to issue its results before the market opens on Friday, August 7th. Analysts expect the company to announce earnings of ($18.60) per share and revenue of $1.6440 million for the quarter.

Exicure (NASDAQ:XCUR) last released its earnings results on Friday, May 29th. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($18.60) by $18.31.

Exicure Price Performance

NASDAQ:XCUR traded up $0.01 during mid-day trading on Wednesday, reaching $1.55. The stock had a trading volume of 15,064 shares, compared to its average volume of 185,407. The company has a market capitalization of $9.87 million, a price-to-earnings ratio of -1.00 and a beta of 3.65. Exicure has a 1-year low of $1.43 and a 1-year high of $9.48. The stock’s 50 day simple moving average is $2.23 and its two-hundred day simple moving average is $3.40.

Wall Street Analyst Weigh In

Separately, Weiss Ratings downgraded Exicure from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, June 11th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has a consensus rating of “Sell”.

About Exicure

Exicure is a clinical?stage biotechnology company pioneering the development of next?generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology?based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard?to?reach tissues such as the central nervous system.

The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology.